Fig. 1From: Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinomaKaplan-Meier estimates of event-free survival. There was no significant difference in EFS between the nICT and nCT groups (HR=1.011, 95% CI: 0.421–2.425, P = 0.981). EFS, event-free survival; nICT, neoadjuvant immunechemotherapy; nCT, neoadjuvant chemotherapyBack to article page